KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationInvestment in Debt & EquityLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Inovio Pharmaceuticals (INO) Accumulated Depreciation & Amortization (2016 - 2025)

Inovio Pharmaceuticals' Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $17.4 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 5.83% to $17.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.4 million, a 5.83% increase, with the full-year FY2025 number at $17.4 million, up 5.83% from a year prior.
  • Accumulated Depreciation & Amortization hit $17.4 million in Q4 2025 for Inovio Pharmaceuticals, up from $16.5 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for INO hit a ceiling of $21.6 million in Q4 2022 and a floor of $89000.0 in Q4 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $15.3 million across 5 years, with a median of $17.4 million in 2025.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: tumbled 55.5% in 2021 and later surged 24128.54% in 2022.
  • Tracing INO's Accumulated Depreciation & Amortization over 5 years: stood at $89000.0 in 2021, then surged by 24128.54% to $21.6 million in 2022, then decreased by 3.3% to $20.9 million in 2023, then decreased by 21.05% to $16.5 million in 2024, then increased by 5.83% to $17.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for INO at $17.4 million in Q4 2025, $16.5 million in Q4 2024, and $20.9 million in Q4 2023.